DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Okazaki M, Ferrandon S, Vilardaga JP, et al. Prolonged signaling
at the parathyroid hormone receptor by peptide ligands
targeted to a specific receptor conformation. Proc Natl Acad
Sci USA, 2008, 105:16525–16530.
Padhi D, Harris R. Clinical pharmacokinetic and pharmacodynamic
profile of cinacalcet hydrochloride. Clin Pharmacokinet, 2009,
48:303–311.
Pak CY, Sakhaee K, Piziak V, et al. Slow-release sodium fluoride
in the management of postmenopausal osteoporosis. A
randomized controlled trial. Ann Intern Med, 1994, 120:
625–632.
Peacock M, Bolognese MA, Borofsky M, et al. Cinacalcet treatment
of primary hyperparathyroidism: Biochemical and bone
densitometric outcomes in a five-year study. J Clin Endocrinol
Metab, 2009, 94:4860–4867.
Perez AV, Picotto G, Carpentieri AR, et al. Minireview on regulation
of intestinal calcium absorption. Emphasis on molecular mechanisms
of transcellular pathway. Digestion, 2008, 77:22–34.
Pike JW, Shevde NK. The vitamin D receptor. In: Vitamin D.
(Feldman D, Pike JW, Glorieux FH, eds.), Elsevier, Burlington,
MA, 2005, pp. 167–191.
Plotkin H, Gundberg C, Mitnick M, et al. Dissociation of bone
formation from resorption during 2-week treatment with
human parathyroid hormone-related peptide-(1-36) in humans:
Potential as an anabolic therapy for osteoporosis. J Clin
Endocrinol Metab, 1998, 83:2786–2791.
Pollak MR, Seidman CE, Brown EM. Three inherited disorders
of calcium sensing. Medicine, 1996, 75:115–123.
Prince R, Sipos A, Hossain A, et al. Sustained nonvertebral
fragility fracture risk reduction after discontinuation of teriparatide
treatment. J Bone Miner Res, 2005, 20:1507–1513.
Purdue BW, Tilakaratne N, Sexton PM. Molecular pharmacology
of the calcitonin receptor. Receptors Channels, 2002, 8:
243–255.
Quamme GA. Molecular identification of ancient and modern
mammalian magnesium transporters. Am J Physiol Cell
Physiol, 2010, 298:C407–429.
Razzaque MS. FGF23-mediated regulation of systemic phosphate
homeostasis: Is Klotho an essential player? Am J
Physiol, 2009, 296:F470–476.
Recker RR, Davies KM, Hinders SM, et al. Bone gain in young
adult women. JAMA, 1992, 268:2403–2408.
Reid IR, Miller P, Lyles K, et al. Comparison of a single infusion
of zoledronic acid with risedronate for Paget’s disease. N Engl
J Med, 2005, 353:898–908.
Richmond VL. Thirty years of fluoridation: A review. Am J Clin
Nutr, 1985, 41:129–138.
Riggs BL, Hodgson SF, O’Fallon WM, et al. Effect of fluoride
treatment on the fracture rate in postmenopausal women with
osteoporosis. N Engl J Med, 1990, 322:802–809.
Rittmaster RS, Bolognese M, Ettinger MP, et al. Enhancement of
bone mass in osteoporotic women with parathyroid hormone
followed by alendronate. J Clin Endocrinol Metab, 2000,
85:2129–2134.
Rogers MJ. New insights into the molecular mechanisms of action
of bisphosphonates. Curr Pharm Des, 2003, 9:2643–2658.
Roodman GD, Windle JJ. Paget disease of bone. J Clin Invest
2005, 115:200–208.
Russell RG. Bisphosphonates: Mode of action and pharmacology.
Pediatrics, 2007, 119 Suppl 2:S150–162.
Schoofs MW, van der Klift M, Hofman A, et al. Thiazide diuretics
and the risk for hip fracture. Ann Intern Med, 2003, 139:
476–482.
Shoback DM, Bilezikian JP, Turner SA, et al. The calcimimetic
cinacalcet normalizes serum calcium in subjects with primary
hyperparathyroidism. J Clin Endocrinol Metab, 2003, 88:
5644–5649.
Selim AA, Mahon M, Juppner H, Bringhurst FR, Divieti P. Role
of calcium channels in carboxyl-terminal parathyroid hormone
receptor signaling. Am J Physiol Cell Physiol, 2006, 291:
C114–C121.
Singh AT, Gilchrist A, Voyno-Yasenetskaya T, et al. Gα 12
/Gα 13
subunits of heterotrimeric G proteins mediate parathyroid hormone
activation of phospholipase D in UMR-106 osteoblastic
cells. Endocrinology, 2005, 146:2171–2175.
Slatopolsky E, Cozzolino M, Lu Y, et al. Efficacy of 19-nor-
1,25-(OH) 2
D 2
in the prevention and treatment of hyperparathyroid
bone disease in experimental uremia. Kidney Int, 2003,
63:2020–2027.
Sneddon WB, Syme CA, Bisello A, et al. Activation-independent
parathyroid hormone receptor internalization is regulated
by NHERF1 (EBP50). J Biol Chem, 2003, 278:43787–43796.
Sowers MF, Clark MK, Jannausch ML, et al. A prospective study
of bone mineral content and fracture in communities with differential
fluoride exposure. Am J Epidemiol, 1991, 133:
649–660.
Spear GT, Paulnock DM, Helgeson DO, et al. Requirement of
differentiative signals of both interferon-gamma and 1,25-
dihydroxyvitamin D 3
for induction and secretion of interleukin-1
by HL-60 cells. Cancer Res, 1988, 48:1740–1744.
Stenbeck G, Horton MA. A new specialized cell-matrix interaction
in actively resorbing osteoclasts. J Cell Sci, 2000, 113:
1577–1587.
Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast
differentiation and function by the new members of the
tumor necrosis factor receptor and ligand families. Endocrine
Rev, 1999, 20:345–357.
Suda T, Ueno Y, Fujii, K, et al. Vitamin D and bone. J Cell
Biochem, 2003, 88:259–266.
Takahashi S, Goldring S, Katz M, et al. Downregulation of calcitonin
receptor mRNA expression by calcitonin during human
osteoclast-like cell differentiation. J Clin Invest, 1995,
95:167–171.
Tashjian AH Jr, Goltzman D. On the interpretation of rat carcinogenicity
studies for human PTH(1-34) and human PTH(1-
84). J Bone Miner Res, 2008, 23:803–811.
Teng GG, Curtis JR, Saag KG. Mortality and osteoporotic fractures:
Is the link causal, and is it modifiable? Clin Exp
Rheumatol, 2008, 26:S125–S137.
Tonino RP, Meunier PJ, Emkey R, et al. Skeletal benefits of alendronate:
7-year treatment of postmenopausal osteoporotic
women. Phase III Osteoporosis Treatment Study Group. J Clin
Endocrinol Metab, 2000, 85:3109–3115.
Tucci JR, Tonino RP, Emkey RD, et al. Effect of three years of
oral alendronate treatment in postmenopausal women with
osteoporosis. Am J Med, 1996, 101:488–501.
Vahle JL, Long GG, Sandusky G, et al. Bone neoplasms in
F344 rats given teriparatide [rhPTH(1-34)] are dependent on
duration of treatment and dose. Toxicol Pathol, 2004, 32:
426–438.
1305
CHAPTER 44
AGENTS AFFECTING MINERAL ION HOMEOSTASIS AND BONE TURNOVER